Skip to main content

Briacell Therapeutics Corp(BCT-T)
TSX

Today's Change
Real-Time Last Update

Stocks in play: BriaCell Therapeutics Corp.

Baystreet - Mon Feb 28, 2022

Has recruited two additional clinical sites for screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat. The additional clinical sites include the following: 1) Atlantic Health System, Morristown, New Jersey, and 2) Tranquil Clinical Research, Webster, Texas. BriaCell Therapeutics Corp. shares T.BCT are trading up $0.18 at $9.86.

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe